Clinical trial
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous…
NCT00135876 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00135876 |
|---|---|
| Title | Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients |
| Official title | A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism, Brain Tumors |
| Intervention type | Drug |
| Interventions | dalteparin |
| Enrollment | 512 |
| Start date | Oct 1, 2002 |
| Completion | Nov 1, 2006 |
| First posted | Aug 26, 2005 |
| Last update posted | Apr 27, 2007 |
| Countries | Australia, Canada, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: